diffuse midline glioma, H3 K27-altered

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27-altered, epithelial neoplasm, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor	Recruiting	Phase 1 / Phase 2	2026-09-11	NCT04870944
A Study of 177Lu-PSMA-617 in People With Gliomas	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), diffuse midline glioma, H3 K27-altered, diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Recruiting	Phase 1	2026-06-04	NCT07223034
Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)	diffuse midline glioma, H3 K27-altered	Not yet recruiting	Phase 1 / Phase 2	2026-05-01	NCT07562971

Clinical trials